Non-Small Cell Lung Cancer

clinical topic updates

by Gregory J. Riely, MD, PhD

Early phase studies suggest that dual targeted therapy might have a role in the treatment of advanced non–small cell lung cancer (NSCLC). Dual targ......READ MORE

clinical topic updates

by Jeffrey Crawford, MD

Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the treatment of late-stage non–small cell lung cancer (NSCLC). Emerging ......READ MORE

clinical topic updates

by Bruce E. Johnson, MD

Immunotherapy has revolutionized the treatment of non–small cell lung cancer (NSCLC). Programmed cell death-ligand 1 (PD-L1) and tumor mutation bur......READ MORE

clinical topic updates

by Gregory J. Riely, MD, PhD

There are several targeted therapies that are approved by the US Food and Drug Administration (FDA) for patients with specific oncogenic alteration......READ MORE

clinical topic updates

by Gregory J. Riely, MD, PhD

Conceptually, a higher tumor mutational burden (TMB), with more mutated, altered proteins, would seem to predict a favorable response to an immunot......READ MORE